FourThought Financial’s NovoCure NVCR Stock Holding History

FourThought Financial’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+17	New	+$1.33K	﹤0.01%	1426
2021 Q4	–	Sell	-20	Closed	-$2K	–	1545
2021 Q3	$2K	Buy	20 +3	+18%	+$454	﹤0.01%	1375
2021 Q2	$3K	Buy	17 +2	+13%	+$389	﹤0.01%	1315
2021 Q1	$1K	Sell	15 -5	-25%	-$791	﹤0.01%	1433
2020 Q4	$3K	Buy	+20	New	+$2.74K	﹤0.01%	1232

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FourThought Financial's NVCR Position: Q3 2022 in Review

FourThought Financial opened a new position in NovoCure (NVCR) in Q3 2022: 17 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1426 among its holdings. This is a return to the name: FourThought Financial previously reported a position in NVCR as recently as Q3 2021.

FourThought Financial first reported a position in NVCR in Q4 2020 and has held it in 5 quarters since. The position peaked at $3K in Q2 2021. 304 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

FourThought Financial held 17 shares of NovoCure worth $1K as of Q3 2022.
NovoCure was a new FourThought Financial position in Q3 2022.
NovoCure made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1426 holding.
FourThought Financial first reported a position in NovoCure in Q4 2020 and has held it in 5 quarters since.
FourThought Financial's NovoCure position peaked at $3K in Q2 2021.
304 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.